Who We Are

Vyteris is the maker of the first active drug delivery patch to receive market approval from the U.S. Food and Drug Administration (FDA). Vyteris was organized in November 2000 as a spinout of the Transdermal Systems unit of Becton Dickinson and Company (BD), to develop, manufacture, and commercialize pharmaceutical products based upon this unique, advanced drug delivery technology. BD created Transdermal Systems just prior to 1990 and invested 10 years and close to $80 million in developing the basis of the Vyteris transdermal drug delivery system.

Vyteris’ proprietary active transdermal drug delivery technology delivers drugs comfortably through the skin using low-level electrical energy. Many of the shortcomings of conventional drug delivery methods can be avoided or minimized. The Vyteris smart patch system delivers drug directly to the blood stream, avoiding metabolism by the liver, and reducing the stomach and gastrointestinal upsets that can be associated with oral drug administration. The system is convenient to use and provides relatively pain free application –avoiding the major drawbacks of injections and intravenous delivery—and delivers drug doses automatically, minimizing concerns about patient compliance. And, Vyteris’ smart patch technology can be utilized for the delivery of many drugs, including many peptides that have, until now, necessitated injections or intravenous infusions.

Learn more about Our Technology and read about our first product, LidoSite^®, in Our Products.

Headquartered in Fair Lawn, New Jersey, Vyteris occupies 27,000 square feet of space devoted to the research, development and manufacturing of transdermal medication delivery products.

We have a portfolio of 181-plus worldwide patents, most of which have a future life of more than 10 years.

Get to know our Management Team.

Read about key members of our Board of Directors.